| Page 1550 | Kisaco Research
 

Dr Peter Beyer

Unit Head, Antimicrobial Resistance Division
WHO

Peter Beyer, a trained lawyer, is a Senior Advisor with the World Health Organization (WHO) in Geneva where he leads a team working on global initiatives on antimicrobial resistance. He focuses on developing global instruments to combat antimicrobial resistance and to foster the development of new antimicrobial treatments.

Read full bio

Dr Peter Beyer

Unit Head, Antimicrobial Resistance Division
WHO

Dr Peter Beyer

Unit Head, Antimicrobial Resistance Division
WHO

Peter Beyer, a trained lawyer, is a Senior Advisor with the World Health Organization (WHO) in Geneva where he leads a team working on global initiatives on antimicrobial resistance. He focuses on developing global instruments to combat antimicrobial resistance and to foster the development of new antimicrobial treatments. Peter was instrumental in setting up the Global Antibiotic R&D Partnership (GARDP), a foundation that is developing new antibacterial treatments as well as the trilateral collaboration among the World Intellectual Property Organization (WIPO), the World Trade Organization (WTO) and WHO. Previously, Peter Beyer was a Legal Advisor to the Swiss Federal Institute of Intellectual Property in Berne. He negotiated bilateral free trade agreements for the European Free Trade Association (EFTA) and was responsible for the bilateral dialogue between Switzerland and China on intellectual property. Prior to joining the Swiss civil service, Peter Beyer worked with the Ecologic Institute in Berlin on environmental law and policy.

 

Andrew Weber

Senior Fellow
The Council on Strategic Risks

Andrew Weber

Senior Fellow
The Council on Strategic Risks

Andrew Weber

Senior Fellow
The Council on Strategic Risks
 

Dr Michael Koeris

Portfolio Executive, NIH RADx COVID-19 Response Program
NIH

Dr Michael Koeris

Portfolio Executive, NIH RADx COVID-19 Response Program
NIH

Dr Michael Koeris

Portfolio Executive, NIH RADx COVID-19 Response Program
NIH
 

Dr Henry Chambers

MD, Professor of Medicine, Emeritus
University of California

Dr Henry Chambers

MD, Professor of Medicine, Emeritus
University of California

Dr Henry Chambers

MD, Professor of Medicine, Emeritus
University of California
 
Targeting Protein Misfolding Congress
15-17 Mar 2021
Virtual Summit
With the neurological drug market now worth $86 billion, and the FDA set to reach a decision on Biogen’s Acudanimib in Spring, whether you’re focused on oncology, Alzheimer’s or ALS, it’s an exciting time to be targeting misfolding diseases.Though there are currently no therapies and cures in this area of drug discovery due to several unmet drug discovery needs. The inaugural Targeting Protein Misfolding Congress will bring together academic and industry leaders, such as Anavex, Ionis Pharmaceuticals, Wren Therapeutics, Arizona State University and University of Florida, who are building platforms to identify and validate targets in protein misfolding diseases and intrinsically disordered proteins to combat these challenges:The lack of appropriate disease models, physiological assays and blood biomarkers to evaluate translation aspects and target engagement.Delivery mechanisms to deliver small molecules and biologics across the blood brain barrier.Determining the true drivers and toxic species in protein misfolding diseases. Mapping the druggable hotspots on protein aggregates and intrinsically disordered proteins to target with small molecules.
Visit Site

Phage Futures Global 2021 - Poster Submission

 

Michael Higgins

Managing Director, Biopharmaceuticals Equity Research
Ladenburg Thalmann & Co. Inc.

Michael Higgins

Managing Director, Biopharmaceuticals Equity Research
Ladenburg Thalmann & Co. Inc.

Michael Higgins

Managing Director, Biopharmaceuticals Equity Research
Ladenburg Thalmann & Co. Inc.
 

Dr Richard Alm

Director of Alliances
CARB-X / Consultant, WHO

Richard joined CARB-X as an Alliance Director following almost 20 years in large pharma Infection R&D teams followed by 4 years at a small antibacterial biotech company.  He has supported the progression of small molecule compounds from discovery through to late-stage clinical development.  He obtained his PhD in molecular microbiology from the University of Adelaide, and prior to joining industry he held two post-doctoral positions in the AMR area, one in Australia and one in Canada.

Read full bio

Dr Richard Alm

Director of Alliances
CARB-X / Consultant, WHO

Dr Richard Alm

Director of Alliances
CARB-X / Consultant, WHO

Richard joined CARB-X as an Alliance Director following almost 20 years in large pharma Infection R&D teams followed by 4 years at a small antibacterial biotech company.  He has supported the progression of small molecule compounds from discovery through to late-stage clinical development.  He obtained his PhD in molecular microbiology from the University of Adelaide, and prior to joining industry he held two post-doctoral positions in the AMR area, one in Australia and one in Canada. Richard is also a consultant on the Global Action Plan on Antimicrobial Resistance for the World Health Organization (WHO).